VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | Investigating the combination of tolinapant & decitabine in a pre-clinical model for T-cell lymphoma

Enrica Marchi, MD, PhD, University of Virginia, Charlottesville, VA, discusses a pre-clinical model which investigated the combination of tolinapant and decitabine in T-cell lymphoma. Dr Marchi highlights the early results from this model and explains the synergistic action of tolinapant and decitabine and its potential application in the treatment of T-cell lymphoma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Research funding: Astex Pharmaceuticals, Merck, Celgene/BMS, NomoCan, Kymera Therapeutics
Scientific advisory: Myeloid Therapeutics, Kyowo Kirin, Daiichi Sankyo

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter